Skip to content
Protalix Looks Beyond Biobetters episode artwork

Jan 22, 2020 24 min

Protalix Looks Beyond Biobetters

from RARECast

Protalix Biotherapeutics plant cell-based platform has been a point of differentiation for the company, a faster and more scalable way of producing protein therapeutics. The company first product, an enzyme replacement therapy for Gaucher disease, offered a proof of its approach. The company is pursuing therapies for Fabry disease and cystic fibrosis, as well as inflammatory diseases, but it is also in the process of rethinking its strategy of biobetters. We spoke to Dror Bashan, CEO of Protalix, about the company’s manufacturing platform, its therapeutic pipeline, and its desire to move toward addressing unmet medical needs.

Episode details come from the podcast's RSS feed.

Embed this episode

Ready to play

Protalix Looks Beyond Biobetters

0:00 24:11

No transcript yet.

Requests help us decide what to transcribe next.

Frequently asked questions

How long is this episode of RARECast?

This episode is 24 minutes long.

When was this RARECast episode published?

This episode was published on January 22, 2020.

Can I download this RARECast episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.